Castle Biosciences’ AdvanceAD-Tx gene expression test for atopic dermatitis has received New York State approval, enabling clinicians to better guide systemic therapy selection for patients with moderate-to-severe disease.
Anthem Blue Cross and Blue Shield will cover C2N Diagnostics’ PrecivityAD2 blood test for Alzheimer’s disease evaluation starting Oct 1, 2026, expanding access to the diagnostic tool for adults with cognitive decline.
A new NIH-funded study finds that elevated circular RNAs in blood may predict Alzheimer’s symptoms years in advance, outperforming current blood tests in forecasting disease progression.
NeoGenomics has launched the first FDA-approved PTEN IHC companion diagnostic for prostate adenocarcinoma, enabling identification of patients with PTEN deficiency who may benefit from AstraZeneca’s capivasertib therapy.
The new service supports transplantation medicine for 13 million people across Northern California and Northern Nevada.
The expanded commercialization agreement aims to increase availability of the GlycoKnow Ovarian laboratory-developed test through Aranscia's clinical workflow and technology platforms.
As autoimmune and allergy test volumes rise, labs are prioritizing workflow standardization and structured testing pathways to ensure reliable results, according to Santhosh Nair, president of immunodiagnostics at Thermo Fisher Scientific.
The assay measures lipoprotein(a) levels in molar units to improve cardiovascular risk assessment and standardization across laboratories.
Presentations will evaluate the performance of the company's pTau217 and pTau181 assays while also highlighting phase 3 clinical research for the investigational therapy trontinemab for Alzheimer's disease.
A two-year real-world study of Renalytix’s FDA-approved KidneyIntelX.dkd test showed improved kidney function and targeted treatment in 2,470 patients with type 2 diabetes.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.